Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT00203411

Public ClinicalTrials.gov record NCT00203411. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Capecitabine (Xeloda) in Frail Patients With Untreated Metastatic Colorectal Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and effectiveness of the bevacizumab and capecitabine combination in frail patients with untreated metastatic colorectal cancer.

Study identification

NCT ID
NCT00203411
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
45 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2006
Primary completion
Feb 28, 2011
Completion
Feb 28, 2011
Last update posted
Feb 5, 2017

2006 – 2011

United States locations

U.S. sites
12
U.S. states
2
U.S. cities
12
Facility City State ZIP Site status
Central Hematology Oncology Medical Group, Inc. Alhambra California 91801
Comprehensive Blood and Cancer Center Bakersfield California 93309
Virginia K. Crosson Cancer Center Fullerton California 92835
Pacific Shores Medical Group Long Beach California 90813
UCLA Medical Center Los Angeles California 90095
North Valley Hematology/Oncology Medical Group Northridge California 91328
Ventura County Hematology-Oncology Specialists Oxnard California 93030
Wilshire Oncology Medical Group, Inc. Pomona California 91767
Cancer Care Associates Medical Group, Inc. Redondo Beach California 90277
Santa Barbara Hematology Oncology Medical Group, Inc. Santa Barbara California 93105
Central Coast Medical Oncology Corporation Santa Maria California 93454
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00203411, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00203411 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →